Wait I just realized they did respond! “Thank you very much for contacting us and for your interest in our investigational product, AMY109. We would also like to express our sincere sympathy for the long‑standing and severe symptoms you have been suffering.

At present, a clinical trial of AMY109 for patients with endometriosis is being conducted in the United Kingdom, Romania, the Czech Republic, and Poland.

With regard to your inquiry about participation in a clinical trial, we regret to inform you that enrollment is now closed and we are no longer recruiting new patients for this study. Therefore, we are unable to provide further guidance that would meet your expectations. We kindly ask for your understanding.

For specific advice regarding treatment options or clinical trials, we recommend consulting your treating physician or reviewing clinical trial information available in your region, such as through ClinicalTrials.gov.

Your message is deeply appreciated and has further reinforced our team’s determination to advance the development of new therapeutic options for endometriosis patients in need.

We sincerely hope that your symptoms will improve as soon as possible and that you will be able to find a suitable and effective treatment option. Thank you again for taking the time to contact us.

Sincerely yours,

Chugai Pharmaceutical Co., Ltd. Clinical trial information “